{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:16:21Z","timestamp":1792790181643,"version":"4.5.0"},"reference-count":32,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swedish Cancer Society","award":["CAN 24 3586 Pj"],"award-info":[{"award-number":["CAN 24 3586 Pj"]}],"id":[{"id":"https:\/\/ror.org\/0527jb766","id-type":"ROR","asserted-by":"crossref"}]},{"award":["CAN 24 3586 Pj"],"award-info":[{"award-number":["CAN 24 3586 Pj"]}],"id":[{"id":"https:\/\/ror.org\/0527jb766","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007190","name":"Government of Sweden","doi-asserted-by":"publisher","award":["ALF-LUA 275108"],"award-info":[{"award-number":["ALF-LUA 275108"]}],"id":[{"id":"10.13039\/501100007190","id-type":"DOI","asserted-by":"publisher"}]},{"award":["ALF-LUA 275108"],"award-info":[{"award-number":["ALF-LUA 275108"]}],"id":[{"id":"https:\/\/ror.org\/04gey0774","id-type":"ROR","asserted-by":"publisher"}]},{"name":"FWO","award":["18B2826N"],"award-info":[{"award-number":["18B2826N"]}]},{"award":["18B2826N"],"award-info":[{"award-number":["18B2826N"]}],"id":[{"id":"https:\/\/ror.org\/03qtxy027","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Hepatitis B surface antigen (HBsAg) loss is rarely achieved during long-term nucleos(t)ide analogue (NUC) therapy of chronic hepatitis B. Treatment discontinuation may lead to immune activation and HBsAg loss. In a prospective study, HBeAg-negative patients without liver cirrhosis stopped NUC therapy after a duration of at least 3 years. Follow-up for 2 years comprised monthly monitoring for the first six months. Twenty-five patients who discontinued therapy and six randomized controls who continued were included. After stopping NUC therapy, five patients (20%) developed an HBsAg seroclearance pattern, including four who lost HBsAg and one who achieved HBsAg below 1 IU\/mL. Seven patients (28%) developed a state of immune control with persistently low HBV DNA and normal ALT. Six patients (24%) experienced severe flares requiring NUC re-initiation; all of them, including one with fulminant hepatitis necessitating liver transplantation, had detectable hepatitis B core-related antigen (HBcrAg) in serum at NUC discontinuation. The peak serum HBV DNA level strongly correlated with and preceded peak ALT. Thus, although half of the patients had favorable outcomes, there was a substantial risk of severe flares preceded by HBV DNA levels above 6 log10 IU\/mL. Close monitoring, including frequent HBV DNA testing with rapid turnaround time, is therefore essential.<\/jats:p>","DOI":"10.3390\/v18091026","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:23:53Z","timestamp":1789496633000},"page":"1026","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune Control, HBsAg Loss or Flare Requiring Liver Transplant\u2014Diverse Outcomes After Stopping NUC Therapy"],"prefix":"10.3390","volume":"18","author":[{"given":"Katarina","family":"Lund","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Norra \u00c4lvsborg\u2019s Hospital, 461 73 Trollh\u00e4ttan, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3346-6320","authenticated-orcid":false,"given":"Miriam","family":"Frankal","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden"},{"name":"Department of Infectious Diseases, S\u00f6dra \u00c4lvsborg\u2019s Hospital, 501 82 Bor\u00e5s, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Anders","family":"Eilard","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden"},{"name":"Department of Infectious Diseases, Sahlgrenska University Hospital, 413 46 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8831-9100","authenticated-orcid":false,"given":"Joakim","family":"Bedner Stenb\u00e4ck","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"given":"Erik","family":"Alestig","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8658-4742","authenticated-orcid":false,"given":"Arno","family":"Furquim d\u2019Almeida","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, 2610 Antwerp, Belgium"},{"name":"Department of Gastroenterology and Hepatology, Antwerp University Hospital, 2650 Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Staffan","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, 413 45 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0572-8741","authenticated-orcid":false,"given":"Thomas","family":"Vanwolleghem","sequence":"additional","affiliation":[{"name":"Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, 2610 Antwerp, Belgium"},{"name":"Department of Gastroenterology and Hepatology, Antwerp University Hospital, 2650 Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-073X","authenticated-orcid":false,"given":"Johan","family":"Westin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden"},{"name":"Department of Infectious Diseases, Sahlgrenska University Hospital, 413 46 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8483-6504","authenticated-orcid":false,"given":"Johan","family":"Ringlander","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8093-2251","authenticated-orcid":false,"given":"Gustaf E.","family":"Rydell","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8729-7462","authenticated-orcid":false,"given":"Magnus","family":"Lindh","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden"},{"name":"Department of Infectious Diseases, Sahlgrenska University Hospital, 413 46 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1053\/j.gastro.2014.03.048","article-title":"Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nationwide cohort study","volume":"147","author":"Wu","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: Finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1053\/gast.2002.36026","article-title":"Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection","volume":"123","author":"Chen","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients\u2014FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: A systematic review","volume":"63","author":"Papatheodoridis","year":"2016","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP3256","article-title":"DARING-B: Discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B","volume":"23","author":"Papatheodoridis","year":"2018","journal-title":"Antivir. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/apt.12908","article-title":"Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides\/nucleotides","volume":"40","author":"Patwardhan","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jhep.2020.11.043","article-title":"Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients","volume":"74","author":"Lens","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1016\/j.cgh.2020.12.005","article-title":"Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)","volume":"20","author":"Sonneveld","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jhep.2024.08.015","article-title":"Predictors of hepatic flares after nucleos(t)ide analogue cessation\u2014Results of a global cohort study (RETRACT-B study)","volume":"82","author":"Dongelmans","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/apt.70465","article-title":"Clinical Trial: Hepatitis B Virus Genotype and a Combination of End-of-Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation","volume":"63","author":"Vanderlinden","year":"2026","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_15","first-page":"e0656","article-title":"Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B","volume":"9","author":"Verbinnen","year":"2025","journal-title":"Hepatol. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/apt.18416","article-title":"Early HBcrAg and Anti-HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation-A Pooled Analysis of Two Clinical Trials","volume":"61","author":"Dongelmans","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1111\/liv.16029","article-title":"High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy","volume":"44","author":"Hume","year":"2024","journal-title":"Liver Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e70630","DOI":"10.1002\/jmv.70630","article-title":"Accurate and Cost-Efficient Whole Genome Sequencing of Hepatitis B Virus Using Nanopore","volume":"97","author":"Schmidt","year":"2025","journal-title":"J. Med. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: Results from a randomised controlled trial (Toronto STOP study)","volume":"68","author":"Liem","year":"2019","journal-title":"Gut"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102257","DOI":"10.1016\/j.clinre.2023.102257","article-title":"Sustained response and HBsAg loss after nucleo(s)tide analogue discontinuation in chronic hepatitis B patients: The prospective SNAP study","volume":"48","author":"Brakenhoff","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/infdis\/jiae541","article-title":"Hepatitis B Virus RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal","volume":"231","author":"Terrault","year":"2025","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/j.gastro.2023.09.033","article-title":"HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy","volume":"166","author":"Sonneveld","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","article-title":"Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B","volume":"214","author":"Rinker","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S2468-1253(19)30344-9","article-title":"Serum alanine aminotransferase flares in chronic hepatitis B infection: The good and the bad","volume":"5","author":"Ghany","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/apt.18147","article-title":"Clinical trial: An open-label, randomised trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B","volume":"60","author":"Johannessen","year":"2024","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/23744235.2025.2555899","article-title":"Viral particles do not contribute significantly to serum levels of hepatitis B surface antigen which is produced mainly from integrated HBV DNA in most patients with chronic hepatitis B","volume":"58","author":"Eilard","year":"2026","journal-title":"Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1093\/infdis\/jiaa572","article-title":"Abundance of Noncircular Intrahepatic Hepatitis B Virus DNA May Reflect Frequent Integration Into Human DNA in Chronically Infected Patients","volume":"225","author":"Rydell","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1111\/liv.15433","article-title":"Low anti-HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen-negative patients","volume":"42","author":"Ohlendorf","year":"2022","journal-title":"Liver Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2022.03.006","article-title":"A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV \u2018cure\u2019","volume":"77","author":"Agarwal","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_30","unstructured":"European Association for the Study of the Liver (2025). EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 83, 502\u2013583."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"100790","DOI":"10.1016\/j.jhepr.2023.100790","article-title":"Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study","volume":"5","author":"Sonneveld","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e081477","DOI":"10.1136\/bmj-2024-081477","article-title":"SPIRIT 2025 statement: Updated guideline for protocols of randomised trials","volume":"389","author":"Chan","year":"2025","journal-title":"BMJ"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/9\/1026\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:23:15Z","timestamp":1789618995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/9\/1026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["v18091026"],"URL":"https:\/\/doi.org\/10.3390\/v18091026","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]}}}